Auriga Partners

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Industries / Tags:

Venture Capital

Detailed Auriga Partners Information

Geographic Data

Auriga Partners headquarters map

Address: 14, Bd de la Madeleine

City: Paris

State: île-de-france

Zip: 75008

Country: FR

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

7,941,076Website Global Rank

414Website Monthly Traffic

Twitter Followers

Description

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
7/2012 Domain Therapeutics Venture Round 2.5M
11/2012 TxCell Series C 16.1M
7/2005 Bag Tech Series B 9.9M
7/2003 Bag Tech Series A 2.9M
7/2008 Bag Tech Series D 2.9M
5/2002 Neolane Series A 1.8M
6/2004 OXAND Venture Round 1.9M
6/2017 Vectalys Venture Round 0
9/2005 SpinX Series B 12.5M
3/2000 Aquarelle Series B 25.5M
1/2010 IDbyME Series A 2.9M
6/2013 Miliboo Series B 5.2M
6/2012 Wallix Venture Round -
1/2007 Neolane Series B 6.5M
11/2011 CYTOO Series C 10M
9/2011 Implanet Series D 7.6M
7/2010 erytech Series B 6.2M
12/2000 Entomed Series B 17.9M
6/2005 Theradiag Series C 6.1M
4/2012 Eptica Venture Round 9.1M
6/2014 Nexthink Corporate Round 20.8M
10/2009 Pharma Omnium Venture Round 109k
8/2007 Median Technologies Series D 4.6M
7/2011 erytech Series C 5.8M
2/2002 Domain Therapeutics Series A 2.6M
11/2013 Implanet Series E 25.3M
4/2014 TxCell Venture Round 21.4M
11/2004 Median Technologies Series B 5.1M
12/2014 Pherecydes Pharma Series A 2.4M
10/2009 CYTOO Series B 4.7M
10/2006 Bag Tech Series C 6.1M
5/2013 aveni Series E 4.5M
5/2022 Vade Secure Venture Round 0
5/2018 Flash Therapeutics Private Equity Round 3.9M
4/2006 Santen Pharmaceutical Post-IPO Equity 31.5M
2/2017 TxCell Post-IPO Equity 11.6M
9/2011 Bonitasoft Series B 11M
4/2013 SuperSonic Imagine Private Equity Round 0
11/2010 SuperSonic Imagine Series C 0
10/2007 Ekinops Series B 20M
1/2007 Nexthink Corporate Round 3.3M
10/1999 Drug Abuse Sciences Venture Round 22.4M
3/2007 Streamcore System Series B 0
2/1999 Aquarelle Series A 4.1M
6/2010 Ekinops Series D 0
5/2009 Ekinops Series C 4M
4/2007 Theraptosis Series B 11.2M
5/2013 Bonitasoft Series C 13M
1/2005 Biolipox Series C 41M
10/2006 Open-Plug Series B 15M
4/2003 Ekinops Series A 7.6M
9/2004 Santen Pharmaceutical Post-IPO Equity 11.2M
5/2007 Implanet Series A 17.7M
5/2004 Domain Therapeutics Series B 19.1M
7/2015 aveni Series A 13.5M
10/2017 aveni Series B 10.5M
11/2013 Nosopharm Venture Round 1.2M
2/2011 CellNovo Series B 48.3M
9/2005 NemeriX Series B 0
9/2007 NemeriX Series C 0
1/2018 Pherecydes Pharma Series B 10.7M
3/2015 Pherecydes Pharma Venture Round 2.7M
12/2001 Hybrigenics Series B 11.6M
11/2003 Santen Pharmaceutical Post-IPO Equity 5.8M
12/2007 NGI Series A 11.8M
2/2007 Pharma Omnium Series D 3M
10/2008 Pharma Omnium Series E 4.2M
10/2001 Gamida Cell Series B 9.7M
11/2005 Pharma Omnium Series C 4.8M
7/2013 Firalis Series B 0
5/2000 Gamida Cell Series A 6.4M
1/2012 Amplitude Series B 39.1M
1/2003 Biolipox Series B 21M
4/2018 EnobraQ Seed Round 3.6M
9/2004 Innate Pharma Series C 0
1/2003 Orexo Series B 22.4M
1/2000 Theradiag Series A 4.6M
3/2009 Stantum Series B 16.4M
12/2009 Genocea Biosciences Series B 25.7M
1/2012 Neolane Venture Round 27M
6/2005 Innovative Silicon Series B 16M
4/2010 Implanet Series C 10.8M
12/2002 Catalyst Bioscience Venture Round 46M
1/2012 IDbyME Series B 0
3/2001 Drug Abuse Sciences Series A 46.5M
8/2005 aveni Series B 14.6M
8/2014 Median Technologies Post-IPO Equity 26.4M
4/2016 Nexthink Series B 48.9M
6/2023 Exeliom Series A 8.7M
3/2017 Nosopharm Venture Round 0
11/2007 Innovative Silicon Series C 25M
7/2018 Exeliom Series A 8.2M
3/2013 Population Genetics Technologies Series G 469k
9/2012 Population Genetics Technologies Series F 1.6M
12/2010 Population Genetics Technologies Venture Round 2.5M
2/2008 Population Genetics Technologies Series A 7.4M
4/2007 aveni Series C 0
6/2022 Patrowl Seed Round 2.1M
5/2003 Theradiag Series B 10.4M
6/2000 Hybrigenics Series A 8.5M
4/2013 erytech Series D 19.3M
5/2012 Gamida Cell Series E 0
7/2006 Median Technologies Series C 12.8M
8/2005 Gamida Cell Series C 3.7M
6/2003 Milagen Series B 3.6M
12/2000 Milagen Series A 839.3k
10/2003 TiGenix Venture Round 14M
1/2011 Miliboo Series A 3.4M
8/1999 ConjuChem Series B 8.5M
5/2014 Convertigo Venture Round 1.5M
6/2017 VitaDX Seed Round 1.8M
6/2014 Wallix Venture Round -
11/2011 Wallix Series A 6.9M
10/2014 aveni Series F 2.8M
2/2000 Spine Next Series A 11.7M
6/2014 Fab&s;entech Series A 6.8M
4/2014 eXo Platform Venture Round 1.2M
3/2010 eXo Platform Series A 6M
9/2009 Convertigo Series A 4.3M
1/2003 Drug Abuse Sciences Series B 1.9M
3/2011 Availpro Series B 3.6M
8/1999 NEMOPTIC Series A 2.5M
2/2013 Codenvy Series A 9M
7/2014 Amoeba Series A 889.1k
10/2013 Genocea Biosciences Series D 16.1M
1/2006 Neolane Series B 6.6M
9/2010 Eve.com Venture Round 454.6k
3/2007 Alchimedics Series A 3.3M
6/2004 Emulation and Verification Engineering Venture Round 7.2M
1/2016 Pylote Venture Round 2.2M
5/2006 NEMOPTIC Series D 0
2/2008 TxCell Series B 15.6M
1/2000 Santen Pharmaceutical Post-IPO Equity 3.8M
3/2003 NEMOPTIC Series C 12M
3/2006 SuperSonic Imagine Series A 11.9M
9/2009 Bonitasoft Series A 3M
5/2004 Pharma Omnium Series B 2.4M
6/2009 Implanet Series B 12.6M
2/2009 Genocea Biosciences Series A 23M
12/2009 Evolva Post-IPO Equity 27.5M
12/2006 Eve.com Series B 6.7M
6/2004 Eve.com Series A 7.2M
4/2007 Nautilus Biotech Venture Round 0
11/2014 Theranexus Seed Round 4.5M
4/2011 Isocell Series A 4.3M
1/2015 CoLucid Pharmaceuticals Series C 0
9/2010 Nexthink Series A 4.9M
3/2004 Innovative Silicon Series A 6M
12/2010 Median Technologies Series E 13.1M
10/2009 Evolva Series B 27.8M
3/2000 Innate Pharma Series A 4.4M
12/2006 erytech Venture Round 15.8M
1/2002 Innate Pharma Series B 17.8M
10/2006 Domain Therapeutics Series C 10.4M
6/2016 One More Company Seed Round -
10/2008 SuperSonic Imagine Series B 25.7M
4/2009 Population Genetics Technologies Series A 3.2M
9/2009 Santen Pharmaceutical Post-IPO Equity 22M
3/2005 Nautilus Biotech Venture Round 0
10/2011 Population Genetics Technologies Series B 5.7M
3/2014 Stantum Venture Round 626.9k
5/2022 Vade Secure Venture Round 0
7/2018 Exeliom Series A 0
5/2018 Flash Therapeutics Private Equity Round 0
4/2018 EnobraQ Seed Round 0
1/2018 Pherecydes Pharma Series B 0
10/2017 aveni Series B 0
6/2017 Vectalys Venture Round 0
6/2017 VitaDX Seed Round 0
3/2017 Nosopharm Venture Round 0
2/2017 TxCell Post-IPO Equity 0

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research
CoBee's Logo
Copyright © CoBee 2022. All Rights Reserved.